Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
12 sept. 2024 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer
12 sept. 2024 07h00 HE
|
Genespire
PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen’s appointment bolsters Genespire’s position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12...
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer
12 sept. 2024 01h00 HE
|
Genespire
PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen’s appointment bolsters Genespire’s position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
09 sept. 2024 16h05 HE
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160...
MDA Kickstart Program Launches for Ultra-Rare Neuromuscular Disease Drug Development
09 sept. 2024 09h00 HE
|
Muscular Dystrophy Association
New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today a new research program called MDA Kickstart for Ultra-Rare Neuromuscular Disease. The MDA...
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
09 sept. 2024 06h30 HE
|
Ocugen
MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
05 sept. 2024 07h00 HE
|
Ocugen
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
04 sept. 2024 07h46 HE
|
ANEW MEDICAL, INC.
Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
03 sept. 2024 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
03 sept. 2024 07h30 HE
|
Ocugen
MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...